What is the most appropriate initial management for a patient with left transverse sinus thrombosis (cerebral venous sinus thrombosis) who presents with a seizure?

Management of Left Transverse Sinus Thrombosis with Seizure

Immediately initiate therapeutic anticoagulation with either intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin, even if imaging shows hemorrhagic transformation, and aggressively treat the seizure with antiepileptic medications. 1, 2

Immediate Anticoagulation (First Priority)

The presence of intracranial hemorrhage related to cerebral venous sinus thrombosis is NOT a contraindication to anticoagulation—withholding anticoagulation in this setting is a critical error. 1, 3 The hemorrhage results from venous congestion and thrombosis itself; anticoagulation prevents further thrombus propagation and reduces mortality. 1

Preferred Initial Anticoagulation Options:

• Low-molecular-weight heparin (LMWH) is the preferred first-line agent: 1

  • Enoxaparin: 1.0 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 1
  • Dalteparin: 200 U/kg subcutaneously once daily 1

• Unfractionated heparin (UFH) is an appropriate alternative when: 1

  • LMWH is contraindicated or unavailable
  • Severe renal failure is present (creatinine clearance <30 mL/min)
  • Thrombolytic therapy may be needed
  • Dosing: Initial bolus of 5000 IU, followed by continuous infusion of approximately 30,000 IU over 24 hours, adjusted to maintain aPTT at 1.5-2.5 times baseline 1

• Obtain baseline coagulation testing (aPTT, INR, platelet count, full coagulation screen) before initiating therapy. 1

Seizure Management (Concurrent Priority)

• Treat seizures aggressively with antiepileptic medications immediately. 1, 2 Seizures occur in approximately 40% of CVST patients, significantly higher than arterial stroke. 2, 4

• Prophylactic antiepileptic therapy is recommended after the first seizure, particularly in patients with hemispheric lesions. 4

• In the case report of left transverse sinus thrombosis, sodium valproate was successfully used for seizure control. 5

Diagnostic Confirmation

• MRI with MR venography (MRV) is the preferred diagnostic modality to confirm the extent of thrombosis and evaluate for hemorrhagic transformation. 3, 2, 6

• CT with CT venography (CTV) is acceptable if MRI is unavailable in the emergency setting. 2, 6

• Non-contrast CT has limited sensitivity (abnormal in only 30% of cases) and should not be used to exclude CVST. 2, 6

Initial Monitoring Protocol

• Perform serial neurological examinations every 2-4 hours during the first 24 hours to detect deterioration (worsening consciousness, new focal deficits, recurrent seizures, signs of increased intracranial pressure). 1

• Obtain repeat non-contrast CT at 24-48 hours after initiating anticoagulation to assess for hematoma expansion or new hemorrhage. 1

• Monitor platelet counts serially throughout anticoagulation to detect possible heparin-induced thrombocytopenia. 1, 7

Setting of Care

• Admission to a stroke unit with stroke-directed nursing care is recommended for initial management to optimize care and minimize complications. 3 Stroke unit care reduces mortality by 14% and death or dependency by 18% compared to general medical wards. 3

Escalation Therapies for Clinical Deterioration

Consider escalation if the patient deteriorates despite adequate anticoagulation:

• Endovascular therapy (mechanical thrombectomy with or without local thrombolysis) should be considered when: 1, 8

  • Progressive neurological decline occurs despite adequate anticoagulation
  • Absolute contraindications to anticoagulation exist
  • Rapid clinical deterioration threatens death

• Decompressive hemicraniectomy is indicated for: 1, 2

  • Severe mass effect causing progressive neurological deterioration
  • Large intracerebral hemorrhage with midline shift
  • Life-threatening herniation risk

Duration of Anticoagulation

• Minimum duration: 3 months for all CVST patients regardless of etiology. 1

• For provoked CVST (transient risk factors such as infection, trauma, recent surgery): 3-6 months. 1, 8

• For idiopathic CVST or mild thrombophilia: 6-12 months. 2, 8

• For recurrent CVST, high-risk thrombophilia, or recurrent venous events: Consider indefinite anticoagulation. 1, 8

Transition to Oral Anticoagulation

• Initiate oral anticoagulants early, continuing parenteral anticoagulation for a minimum of 5 days and until INR ≥2.0 for at least 24 hours. 1

• Target INR range of 2.0-3.0 (target 2.5) for vitamin K antagonists. 1

Follow-up Imaging

• Follow-up CT venography or MR venography at 3-6 months is reasonable to assess for recanalization of the occluded sinuses in stable patients. 3, 1, 2

• The duration of anticoagulation is NOT determined by the presence or absence of radiographic recanalization. 1

Critical Pitfalls to Avoid

• Never withhold anticoagulation due to hemorrhage on imaging—hemorrhagic venous infarction is an indication FOR, not against, anticoagulation. 1

• Do not rely on non-contrast CT alone to exclude CVST; proceed to CTV or MRV if clinical suspicion remains high. 2, 6

• Do not delay anticoagulation while awaiting thrombophilia workup—treatment should begin immediately upon diagnosis. 1, 9